Forte Biosciences, Inc.
DelistedCIK 1419041fmd_07GW4NNXFAQ7KZG41T462EWEX9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2026, 43 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 18 | 0 | – | – | – | – | – | – |
| Net interest income | – | – | – | – | – | – | 0 | 1 | 1 | 3 |
| Research and development | 27 | 29 | 51 | 3 | 10 | 14 | 6 | 22 | 21 | 58 |
| Total operating expenses | 32 | 38 | 64 | 4 | 46 | 21 | 14 | 32 | 37 | 71 |
| Operating income | (32) | (38) | (46) | (4) | (46) | (21) | (14) | (32) | (37) | (71) |
| Interest expense | 2 | 2 | 3 | 4 | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | (1) | – | (0) | (0) | (0) | (0) | (0) | 1 | 2 |
| Income before taxes | (33) | (39) | (47) | (64) | – | – | – | (31) | (35) | (68) |
| Income tax expense | 0 | 0 | 2 | 0 | – | – | – | – | 0 | 1 |
| Net income from continuing operations | (33) | (39) | (49) | (64) | – | – | – | – | (35) | (69) |
| Net income | (33) | (39) | (49) | (4) | (46) | (22) | (14) | (31) | (35) | (69) |